Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: The presentations will be webcast live and can be accessed at www.incyte.com in the Investors section …
With no debt on the balance sheet and $1.54 bn in 2017 sales, Incyte is still a "sensible" buying opportunity even as its stock is up from the $80.85 53-wk low on 2/9/18. Incyte has a diverse pipeline of JAK1/JAK2, IDO1, PI3K-delta, and …
Analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +92.00% heading into earnings season. Incyte Corporation Price and EPS Surprise Incyte Corporation Price and EPS Surprise | …
The Phase 3 trail was to determine the effectiveness of Incyte Corporation’s epacadostat in treating patients with unresectable or metastatic melanoma in combination with Merck & Co., Inc.’s (NYSE:MRK) KEYTRUDA. Unfortunately …
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: The presentations will be webcast live and can be accessed at www.incyte.com in the Investors section …
KLTV27d
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: The presentations will be webcast live and can be accessed at www.incyte.com in the Investors section …
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: The presentations will be webcast live and can be accessed at www.incyte.com in the Investors section …
KRGV27d
Jakafi is being tested in a late-stage study for graft versus host disease, and results are expected in the first half of 2018, this could end up boosting the stock. Recently, Incyte Corporation (INCY) fell as much as 20% after the company …